ropinirole hydrochloride: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
ropinirole hydrochloride: clinical details
Prescribing considerations
- Confirm that restless legs syndrome is idiopathic and moderate to severe.
- Assess somnolence, sudden sleep episodes, hallucinations, psychosis, mania, impulse-control disorders and dopamine dysregulation syndrome.
- Assess dyskinesia with concurrent levodopa in Parkinson’s disease.
- Review hepatic and renal function, cardiovascular disease, smoking status and interacting medicines.
- Avoid abrupt withdrawal; monitor for withdrawal symptoms.
Contraindications and cautions
- Hypersensitivity to ropinirole or a product excipient
- Severe renal impairment without regular haemodialysis
- Hepatic impairment
- Product-specific excipient restrictions, including rare hereditary disorders affecting lactose handling
Monitoring
- Clinical response and tolerability
- Blood pressure when hypotension is suspected
- Daytime sleepiness and sudden sleep onset
- Impulse-control behaviours, mania, hallucinations and psychotic symptoms
- Restless legs augmentation or early-morning rebound
- Withdrawal symptoms during discontinuation
- INR with a vitamin K antagonist
Clinical pharmacology
Ropinirole is a non-ergoline D2/D3 dopamine receptor agonist, metabolised mainly through CYP1A2.
Formulation and product differences
- The selected immediate-release tablet is licensed for Parkinson’s disease and moderate to severe idiopathic restless legs syndrome.
- The selected prolonged-release tablet is licensed for Parkinson’s disease only.
- The selected immediate-release tablet may be divided into equal halves.
- Prolonged-release tablets must be swallowed whole.
- A high-fat meal can increase exposure from the prolonged-release formulation.
ropinirole hydrochloride preparations and strengths
Modified-release tablet
Route: Oral
Strengths: 2 mg, 4 mg, 8 mg
Tablet
Route: Oral
Strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 2.0 mg, 5 mg
ropinirole hydrochloride interactions
Tell the prescriber or pharmacist about all medicines, supplements and changes in smoking.
Metoclopramide, sulpiride and other central dopamine antagonists
They can oppose ropinirole’s effect and reduce effectiveness; combined use is generally avoided.
Ciprofloxacin, enoxacin, fluvoxamine and other CYP1A2 inhibitors
They can increase ropinirole exposure and adverse effects.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.